Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates

Frédéric B Piel, Anand P Patil, Rosalind E Howes, Oscar A Nyangiri, Peter W Gething, Mewahyu Dewi, William H Temperley, Thomas N Williams, David J Weatherall, Simon I Hay, Frédéric B Piel, Anand P Patil, Rosalind E Howes, Oscar A Nyangiri, Peter W Gething, Mewahyu Dewi, William H Temperley, Thomas N Williams, David J Weatherall, Simon I Hay

Abstract

Background: Reliable estimates of populations affected by diseases are necessary to guide efficient allocation of public health resources. Sickle haemoglobin (HbS) is the most common and clinically significant haemoglobin structural variant, but no contemporary estimates exist of the global populations affected. Moreover, the precision of available national estimates of heterozygous (AS) and homozygous (SS) neonates is unknown. We aimed to provide evidence-based estimates at various scales, with uncertainty measures.

Methods: Using a database of sickle haemoglobin surveys, we created a contemporary global map of HbS allele frequency distribution within a Bayesian geostatistical model. The pairing of this map with demographic data enabled calculation of global, regional, and national estimates of the annual number of AS and SS neonates. Subnational estimates were also calculated in data-rich areas.

Findings: Our map shows subnational spatial heterogeneities and high allele frequencies across most of sub-Saharan Africa, the Middle East, and India, as well as gene flow following migrations to western Europe and the eastern coast of the Americas. Accounting for local heterogeneities and demographic factors, we estimated that the global number of neonates affected by HbS in 2010 included 5,476,000 (IQR 5,291,000-5,679,000) AS neonates and 312,000 (294,000-330,000) SS neonates. These global estimates are higher than previous conservative estimates. Important differences predicted at the national level are discussed.

Interpretation: HbS will have an increasing effect on public health systems. Our estimates can help countries and the international community gauge the need for appropriate diagnoses and genetic counselling to reduce the number of neonates affected. Similar mapping and modelling methods could be used for other inherited disorders.

Funding: The Wellcome Trust.

Copyright © 2013 Elsevier Ltd. All rights reserved.

Figures

Figure 1
Figure 1
Schematic overview of the methods and Bayesian model-based geostatistical analysis HbS=sickle haemoglobin. Positive=number of HbS alleles in the population sample. Negative=number of non-HbS alleles in the population sample. Mbg-infer=model-based geostatistical inference process based on a Markov chain Monte Carlo (MCMC) algorithm. GRUMP=Global Rural Urban Mapping Project. Mbg-map=model-based geostatistical mapping process. Mbg-areal-predict=model-based geostatistical areal prediction process. AS=HbS heterozygotes. SS=HbS homozygotes.
Figure 2
Figure 2
Datapoint distribution and maps of the mean and uncertainty in the predicted HbS allele frequency (A) Distribution of the datapoints. Red circles and blue triangles indicate surveys showing presence and absence of HbS, respectively. (B) Mean of the posterior predictive distribution. (C) Bayesian model-based geostatistics prediction uncertainty (posterior standard deviations) of the HbS allele frequency.
Figure 3
Figure 3
Comparison plots of predicted national SS neonate estimates with Modell and Darlison's estimates for the AFRO and AMRO regions Red dots show our estimates (termed MAP) with IQRs shown as red lines. Blue dots represent Modell and Darlison's estimates. (A) AFRO. (B) AMRO. AFRO=Regional Office for Africa. AMRO=Regional Office for the Americas.
Figure 4
Figure 4
Comparison plots of predicted national SS neonate estimates with Modell and Darlison's estimates for the EMRO and EURO regions Red dots show our estimates (termed MAP) with IQRs shown as red lines. Blue dots represent Modell and Darlison's estimates. (A) EMRO. (B) EURO. EMRO=Regional Office for the Eastern Mediterranean Countries. EURO=Regional Office for Europe.
Figure 5
Figure 5
Comparison plots of predicted national SS neonate estimates with Modell and Darlison's estimates for the SEARO and WPRO regions Red dots show our estimates (termed MAP) with IQRs shown as red lines. Blue dots represent Modell and Darlison's estimates. (A) SEARO. (B) WPRO. SEARO=Regional Office for South-East Asia. WPRO=Regional Office for the Western Pacific.

References

    1. Weatherall D, Akinyanju O, Fucharoen S, Olivieri N, Musgrove P. Inherited disorders of hemoglobin. Disease control priorities in developing countries. 2nd edn. Oxford University Press; New York: 2006. pp. 663–680.
    1. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376:2018–2031.
    1. Williams TN, Obaro SK. Sickle cell disease and malaria morbidity: a tale with two tails. Trends Parasitol. 2011;27:315–320.
    1. Piel FB, Patil AP, Howes RE. Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis. Nat Commun. 2010;1:104.
    1. Allison AC. Protection afforded by sickle-cell trait against subtertian malareal infection. BMJ. 1954;1:290–294.
    1. Cavalli-Sforza LL, Menozzi P, Piazza A. The history and geography of human genes. Princeton University Press; Princeton, NJ, USA: 1994.
    1. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86:480–487.
    1. Rajaratnam JK, Marcus JR, Flaxman AD. Neonatal, postneonatal, childhood, and under-5 mortality for 187 countries, 1970-2010: a systematic analysis of progress towards Millennium Development Goal 4. Lancet. 2010;375:1988–2008.
    1. Williams TN, Uyoga S, Macharia A. Bacteraemia in Kenyan children with sickle-cell anaemia: a retrospective cohort and case-control study. Lancet. 2009;374:1364–1370.
    1. Gething PW, Smith DL, Patil AP, Tatem AJ, Snow RW, Hay SI. Climate change and the global malaria recession. Nature. 2010;465:342–345.
    1. Livingstone FB. Aspects of the population dynamics of the abnormal hemoglobin and glucose-6-phosphate dehydrogenase deficiency genes. Am J Hum Genet. 1964;16:435–450.
    1. Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood. 2010;115:4331–4336.
    1. Panepinto JA, Magid D, Rewers MJ, Lane PA. Universal versus targeted screening of infants for sickle cell disease: a cost-effectiveness analysis. J Pediatr. 2000;136:201–208.
    1. Akinyanju O. The national burden of sickle cell disorder and the way forward. Sickle Cell Foundation Nigeria; 2010. (accessed Nov 15, 2011).
    1. Balgir RS. The burden of haemoglobinopathies in India and the challenges ahead. Curr Sci. 2000;79:1536–1547.
    1. Weatherall DJ. The challenge of haemoglobinopathies in resource-poor countries. Br J Haematol. 2011;154:736–744.
    1. Patil AP, Gething PW, Piel FB, Hay SI. Bayesian geostatistics in health cartography: the perspective of malaria. Trends Parasitol. 2011;27:246–253.
    1. Gething PW, Patil AP, Hay SI. Quantifying aggregated uncertainty in Plasmodium falciparum malaria prevalence and populations at risk via efficient space-time geostatistical joint simulation. PLOS Comput Biol. 2010;6:e1000724.
    1. Hardy GH. Mendelian proportions in a mixed population. Science. 1908;28:49–50.
    1. Weinberg W. Über den Nachweis der Vererbung beim Menschen. Jahresh Wuertt Verh Vaterl Naturkd. 1908;64:369–382.
    1. Guerra CA, Hay SI, Lucioparedes LS. Assembling a global database of malaria parasite prevalence for the Malaria Atlas Project. Malar J. 2007;6:17.
    1. Guerra CA, Howes RE, Patil AP. The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl Trop Dis. 2010;4:e774.
    1. World population prospects: The 2010 revision. (accessed July 15, 2011).
    1. Alexander N, Higgs D, Dover G, Serjeant GR. Are there clinical phenotypes of homozygous sickle cell disease? Br J Haematol. 2004;126:606–611.
    1. Hay SI, Okiro EA, Gething PW. Estimating the global clinical burden of Plasmodium falciparum malaria in 2007. PLoS Med. 2010;7:e1000290.
    1. World Health Organization Regional Office for Africa . Sickle-cell disease: a strategy for the WHO African Region. Report of the Regional Director. WHO; Equatorial Guinea: 2010. (accessed Oct 30, 2011).
    1. Livingstone FB. Frequencies of hemoglobin variants: thalassemia, the glucose-6-phosphate dehydrogenase deficiency, G6Pd variants and ovalocytosis in human populations. Oxford University Press; New York: 1985.
    1. UN The United Nations Demographic Yearbook, 2003. (accessed Nov 15, 2011).
    1. Streetly A. A national screening policy for sickle cell disease and thalassaemia major for the United Kingdom. Questions are left after two evidence based reports. BMJ. 2000;320:1353–1354.
    1. Allison AC. Genetic control of resistance to human malaria. Curr Opin Immunol. 2009;21:499–505.
    1. Weatherall DJ. The importance of micromapping the gene frequencies for the common inherited disorders of haemoglobin. Br J Haematol. 2010;149:635–637.
    1. Dyson SM, Atkin K. Genetics and global public health: sickle cell and thalassaemia. Routledge; London: 2012.
    1. Bittles AH. Endogamy, consanguinity and community disease profiles. Community Genet. 2005;8:17–20.
    1. Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38(suppl 1):S512–S521.
    1. Williams TN, Mwangi TW, Wambua S. Negative epistasis between the malaria-protective effects of alpha+-thalassemia and the sickle cell trait. Nat Genet. 2005;37:1253–1257.
    1. Penman BS, Pybus OG, Weatherall DJ, Gupta S. Epistatic interactions between genetic disorders of hemoglobin can explain why the sickle-cell gene is uncommon in the Mediterranean. Proc Natl Acad Sci USA. 2009;106:21242–21246.

Source: PubMed

Подписаться